Tigermed's first quarter net profit declines amid revenue dip

Hangzhou Tigermed Consulting Co., Ltd. (HKEX:3347) today announced its first-quarter results for 2025, revealing a decrease in both revenue and net profit. Revenue saw a 5.79% year-over-year decline, landing at CNY1,564.14 million. Net profit attributable to shareholders of the listed company fell 29.61% to CNY165.47 million. Basic and diluted earnings per share both dropped to CNY0.19. The company's net cash flows from operating activities increased by 37.26% to CNY197.93 million. The company noted a continued growth momentum in total newly-signed orders, with a significant recovery from domestic clients. Newly-added contract amount exceeded CNY2 billion, up 20% year-over-year. Tigermed stated that reclassification of interest income as well as strategic investment in digital technologies influenced financial results.